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Biological therapies targeting arrhythmias: are cells and genes the answer? 
Abstract  
Introduction: The clinical presentation of arrhythmias ranges from mild symptoms such as 
dizziness, to life-threatening circulatory collapse. Current management includes medical 
therapy and procedures such as ablation or device implantation, however these strategies still 
pose a risk of side effects, while some patients remain symptomatic. Areas covered: 
Advancement in our understanding of how arrhythmias develop on the cellular level has made 
more targeted approaches possible. In addition, contemporary studies have found that several 
genes are involved in the pathogenesis of arrhythmias. Interestingly, gene and cell therapies 
allow treatments to be locally applied, bypassing systemic side effects in most occasions. 
Expert opinion: Pre-clinical studies have shown promising results in animal models of 
arrhythmias. However, more work is needed before this becomes a clinically viable option. 
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Introduction  
 The principle mechanisms of arrhythmias can be divided into disorders of impulse 
formation (triggered activity or automaticity) or impulse conduction (reentry)[1, 2]. Ion 
handling by the cardiomyocyte is a delicate process, the disruption of which can lead to 
disordered cardiac excitation and arrhythmias [3].  
Genetic mutations can result in altered ion movement, even within a structurally normal 
heart. Changes to sodium, potassium and calcium handling distorts the cardiac action potential, 
resulting in altered depolarization or repolarization. Mutations, primarily within ion channel 
genes, underlie conditions such as Long QT Syndrome (LQTS) and Brugada [4], and less 
commonly bradyarrhythmias [5].  
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 Most arrhythmias occur in the presence of structural heart disease where the cell 
structure has been altered, resulting in profound ion dysregulation [6]. Ischaemia converts 
conducting tissue into an electrically inactive scar, forcing the wave front into a region of slow-
conducting tissue, creating an environment suitable for reentry[2, 7]. Fibrosis occurs in 
pacemaker cells as part of the aging process, resulting in bradycardia [8]. 
 Recent studies have used gene and cell therapy to alter impulse formation and impulse 
conduction properties. Genes of interest can be transferred using a viral or non-viral vector and 
delivered to the target area using direct injection or catheter-based techniques[9]. Gene transfer 
has been used to treat ventricular arrhythmias, bradycardia and atrial fibrillation within animal 
models[10]. Cell transplantation, generally embryonic or mesenchymal stem cells, can repair 
or improve conduction in animal heart disease models [7] 
 In the present review article, we aim to summarize the most up-to-date work in cell and 
gene therapy, and what the next steps are in making this is clinically viable option for 
arrhythmias. 
 
Cell mechanisms of ventricular tachycardia and ventricular fibrillation 
 Ventricular tachycardia (VT) or fibrillation (VF) occur as a result of cell membrane 
hyperexcitability, disturbed repolarisation or defective conduction of the electrical wavefront 
across the myocardium [11].   Most monomorphic VTs occur in the presence of structural heart 
disease, caused by reentry secondary to electrically inactive scar tissue post- myocardial 
infarction. This forces the wavefront to propagate around a line of block, and enters the area 
behind the scar [6].   The non-conductive tissue creates disruptions in gap junctions and poor 
cell coupling, which subsequently slows conduction and/or creates a unidirectional block: these 
are conditions ideal for development of reentrant arrhythmias. The wave front enters an area 
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behind scar, and if it reaches the back of the obstacle from multiple directions simultaneously 
then waves extinguish one another. However, if unidirectional block exists around one side, 
the wave front can reenter and re-excite tissue in front of unidirectional block, leading to stable 
reentry [6]. 
Disturbed ion channel function can also occur in structurally normal myocardium.  In 
this instance, ventricular tachycardia is thought to arise because of triggered activity or 
automaticity.  Both early afterdepolarizations (EADs) and delayed afterdepolarizations 
(DADs) can reach the threshold high enough to trigger premature ventricular contractions, 
these can subsequently dissipate into monomorphic or polymorphic VT [2]. 
 
 
 
Cell mechanisms of bradyarrhythmias  
                  Reduce automaticity is the underlying mechanism in bradycardia. Conduction 
delay and block occurs when propagating impulse fails to conduct.  One of the main causes of 
bradycardia is sinus node dysfunction. This causes depression of the automaticity in the 
sinoatrial node (SAN) and thus impairs electrical conduction from the sinus node, perinodal 
and atrial tissue [12, 13].  
The most common cause of sinus node dysfunction is idiopathic degenerative fibrosis 
of nodal tissue that results as a normal part of the ageing process. Fibrosis leads to a loss of 
pacemaker cells, and a shift from central to inferior pacemaker cells within the 
SAN. Spontaneous diastolic depolarisation is slower in those cells leading to bradycardia [12, 
13].  
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Cell mechanisms of atrioventricular tachycardia.  
                Atrioventricular Nodal Reentrant Tachycardia (AVNRT) is caused by a reentrant 
mechanism.  It occurs secondary to the presence of two pathways within the AV node which 
have different electrophysiological properties.   It occurs as the fast pathway that exists has 
rapid conduction and a longer refractory period in comparison to the atrioventricular node, 
creating a substrate for reentry. The impulse will travel through both pathways in normal 
conditions. In the presence of a premature stimulate, the stimulus blocks in the faster pathway 
due to a longer refractory period and travels through the slower accessory pathway. If slow 
enough, the blocked pathway can have time to recover, setting the state for reentry.  In response 
to a premature stimulation, the stimulus can block in the fast pathway due to a longer refractory 
period and travel through the slow pathway. If conduction is slow enough, the blocked fast 
pathway can have time to recover, thus setting the stage for a reentrant circuit, translating into 
AV nodal tachycardia when perpetuated.  
In atrioventricular nodal tachycardia (AVRT), an accessory pathway exists that has a more 
rapid conduction and longer refractory period in comparison to the AV node, also leading to re-
entry [1]. 
  
Cell-based therapies  
                 Cell therapy offers a novel approach to arrhythmias (Table 1).  Research data has 
shown that cell transplantation can improve or repair impulse conduction in vitro and in 
experimentally injured animal hearts in vivo [7]. There has been heavy focus on the use of 
biological pacemakers to treat bradycardias caused by SAN dysfunction or complete AV block. 
In this case, cells are used to enhance tissue automaticity or repair damaged conduction such 
as AV block to restore normal heart rhythm. For tachyarryhythmias the focus is instead to 
reduce myocardial excitability or repair damage to break reentrant circuits [14].  
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Proof of concept has been provided using a variety of approaches to increased inward 
current or decreased repolarising current as a basis for propagation of a pacemaker potential 
[8]. In this arena of research, both embryonic stem cells and human mesenchymal stem cells 
have been the main area of focus, although other cell sources (skeletal myoblasts; fibroblasts; 
cardiac stem cells) have been utilised. Both need electrical integration into host myocardium 
to allow for initiation of pacemaker activity however this does not involve further engineering 
because both successfully form functional gap junctions with adjacent myocytes due to 
abundant connexin expression [15] .  
The aim of cell therapies is to restore normal function of the conduction system in the 
heart by transplantation of appropriate cell populations  [16]. Two strategies have been 
explored with regards to formation of cell-based biological therapy for use in 
arrhythmogenesis. The first involves the injection of inexcitable cells expressing inward 
current that depolarises neighbouring cells to their action potential threshold.  This method 
requires at least two cells to create a pacing unit.  The second strategy, involves the injection 
of excitable cells with the ability to generate spontaneous action potentials. In this method, the 
delivered cells are the biological pacemakers.  In both strategies, the assumption is that 
coupling will occur through gap junction formation between donor cells and between donor 
and target cells.  Gap junctions are required for the initiation of intercellular current flow, and 
allowing the delivered cells to integrate electromechanically into the cardiac environment [17].  
 
Embryonic stem cells 
Use of embryonic stem cells for the treatment of bradyarrhythmias    
A major barrier for the development of cell replacement strategies is the paucity of cell 
sources for human cardiomyocytes. A proffered solution has been human embryonic stem cells 
(hESCs). They are one agent being heavily utilised in the development of cell based therapies 
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for cardiac arrhythmias.  They are suitable in that they are pluripotent and can differentiate into 
any cell type, including pacemaker cells [15, 18]. They are also clonogenic and self–
propagating [19], able to generate unlimited numbers of functional cadiomyocytes.  
HESCs can differentiate in vitro and they form embryoid bodies (hEBs) composed of 
derivatives of all 3 embryonic germ layers. They are heterogenous, and some begin to contract 
spontaneously, containing cardiac myocytes that exhibit phase 4 depolarisation [20-22]. It has 
been demonstrated that these cardiomyoctes have the capability of forming a functional 
"cardiac synctium" responsive to adrenergic and cholinergic stimuli [16].  
Studies demonstrate that biological pacemakers derived from hESCs are capable of 
pacing recipient ventricular cardiomyocytes in vitro and myocardium in vivo 
[23].  Cardiomyocytes derived from hESCs can electromechanically integrate with 
cardiomyocytes in culture. The first reported use of ESCs to create biological pacemakers was 
by Kehat and colleagues [24]. They showed that cardiomyocytes derived from hESCs can 
electromechanically integrate with cultures of neonatal ventricular myocytes.  Electrograms 
recorded from sixty electrodes of a multi-electrode array showed initiation and conduction 
within the co-culture. Following addition of cardiomyocytes derived from hESCs, electrograms 
demonstrated tight temporal coupling between human and rat cells within one day, and lasted 
until the end of the experiment [25].  
In further studies, it was highlighted that clusters of such cells could integrate into host 
myocardium in a large animal model of complete heart block, providing a proof of concept for 
the use of cell therapy to generate a biological pacemaker. The cells demonstrated normal 
cardiac excitation contraction coupling demonstrated within this tissue, electrical activation, 
increased in [ca2+]I and the following contraction [25].  
Kehat et al. derived spontaneously-beating hEBS from cultured ESCs and implanted 
these into pig ventricles with complete heart block. Rhythm showed a positive chronotropic 
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response upon exposure to isoproterenol administration- mimicking physiological pacemaker 
function. Stable pacing was observed in half; the remaining had only ectopics orginating from 
the site of implantation, others failed to demonstrate reliable pacing [23, 25].  Xue et al.  used 
a different strategy. They injected cardiomyoctes derived from hESCs into the subepicardium 
of the left ventricle of guinea pigs. The result was the functional integration of these cells with 
host tissue and to induce electrical activity to injection site to adjacent cardiac tissue [26].  It is 
important to note that the hosts required immunosuppression [23].  
A further in vivo model was developed, whereby hEBs were injected into left 
ventricular anterior wall of a guinea pig [27]. A single hESC-derived hEB was transplanted on 
a monolayer of neonatal ventricular rat myocytes (NVRMs) serving as host. Spontaneously 
beating hEB and a monolayer of quiescent rat myocytes were co-cultured and demonstrated 
expression of gap junctions at their boundary and rhythmic contractions of the hEB. Multi-
electrode and optical mapping showed that spontaneous APs propagated to the NVRMS. The 
hESC-derived biological pacemakers spontaneously beat prior to transplantation and could be 
a good way to generate a spontaneous rhythm in the bradycardic setting. Immune response 
from the host remains the main caveat in these therapies becoming a reality, although these 
could be overcome by induced pluripotent stem cells [8]. Whilst recent studies have shown 
that hESC-CMs mature over time in culture to show a more adult phenotype, there are also 
concerns that ESC and induced pluripotent cell implants would lose pacing ability over 
time [28].  
 
Use of embryonic stem cells in the treatment of tachyarrythmias  
Whilst studies have mainly focused on the use of cell therapy for SAN damage, and 
AV block, their use for tachyarrythymias has also been noted, mainly post-infarct[29-
31]. Myocardial ischemia leads to cardiomyocyte death. Mature human cardiomyocytes 
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have limited ability to regenerate, and so dead myocardium is replaced by scar tissue formed 
from fibroblasts; these are non-excitable with low levels of connexin expressed. As such, this 
scar tissue has limited capability to conduct electrical impulses leading to slowed conduction 
or even conduction block [32] and is essentially an arrhythmogenic focus [29]. The suggestion 
is that hESC-CMs can reduce the likelihood of reentrant arrhythmias under certain conditions 
such as post-infarct fibrosis [29].  
Reentry is responsible for approximately 85% of arrhythmias that follow 
myocardial ischaemia or infarction [33], leading to ventricular tachycardias and fibrillation. 
Thompson et al. observed a decrease in incidence of re-entrant waves after engraftment 
of hESC-CMs in monolayers but not with the non-beating human embryoid cell engraftment 
[29]. This not unlike another study which showed that engraftment of eCMs in myocardial 
infarcted tissue reduced incidence of ventricular tachycardia in mice. It is thought that this can 
be attributed to a decrease in "heterogeneity of conduction" or increase in wavelength of 
the propagating wave. hESC CMS effectively lower resting potential of host myocytes [34]. 
 
Mesenchymal Stem Cells  
Use of mesenchymal stem cells in the treatment of bradyarrythmias  
Mesenchymal stem cells (MSCs) are a subset of stromal stem cells that can be isolated 
from many adult tissues [35]. It is suggested that they may be better than ESCs in terms of 
clinical application. Several trials have been performed and the possibility is that they are 
immunoprivileged; there have been no immune responses so far [15, 35]. They are, in contrast 
to ESCs, multipotent and only able to differentiate into cells of the mesoderm lineage and as 
such need genetic modification in order to incorporate pacemaker properties [15]. 
Synchronously beating monolayers of culture neonatal rat cardiomyocytes in a MEA 
dish were separated by mechanically abraded channels to yield two asynchronously beating 
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cardiomyocyte fields. Adding hMSCs to abraded channel resynchronised the two separated 
cardiomyocyte fields and conduction velocity across hMSCs increased progressively after co-
culture with cardiomyoctes. Cx43 expression and functional gap junctions were formed 
between hMSCs and cardiomyocytes with such electrical connections increasing following 
time after co-culture [36]. Adding hMSCs to cultures of isolated dog ventricular myocytes also 
formed cx43 and cx40 connections along regions cell-to cell contact, leading to cell-to cell 
coupling [37].  
Local implantation of MSCS into the AVN area improved AV conduction in rat model 
with complete AVN block [38]. Animals with MSC transplantation showed significantly 
decreased collagen deposition in the AVN area.  This is thought to potentially be due to 
paracrine effects of implanted MSCS and anti-fibrotic properties leading to improvement of 
impulse conduction.  However, co-culture of hMSCs with neonatal rat ventricular myocytes 
decreased conduction velocity and induced reentrant arrhythmias probably due to tissue 
heterogeneity of inexcitable MSCs and myocytes [39]. One study showed integration could be 
improved: infarcted rat hearts implanted with cardiogenic cells developed from rat MSCS after 
treatment with a PKSC activator restored conduction velocity, by means of reducing tissue 
heterogenity and improving myocardial contractility [40]. 
 
Use of mesenchymal stem cells in the treatment of tachyarrythmias  
The aforementioned principles have been demonstrated to show potential with regards 
to clinical application.  Katrisis et al followed patients with history of MI with ICDs 
and performed intracoronary MSC and endothelial progenitor cell transplantation. Prior to 
stem cell transplantation, non-sustained VT inducible monomorphic VT or ventricular flutter 
observed in all 5 patients. At 16-36 months follow up, interrogation of ICD failed to detect any 
further episodes of ventricular arrhythmia, and further electrophysiological study induced 
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sustained ventricular arrhythmias in only 2 patients.  This however is a small, non-
randomised study, only preliminary in nature [41].  
 
Alternative cell sources   
Myoblasts  
Myogenic precursor cells are also alternative sources that have been investigated. 
Myoblasts can be harvested from skeletal muscle biopsy. Primary myoblasts have capability 
of division and expansion to offer a rich cell source for transplantation.  They have been 
transplanted autologously for myocardial repair. [42]. Ventricular tachyarrrythmias and sudden 
cardiac death due to failure of gap junction formation s has been observed in clinical trials with 
myoblast transplantation [43]. Cocultures of human skeletal myoblasts and rat cardiomyoctes 
reproduced reentrant arrhythmias; addition of calcium channel blocker nitrendipline blocked 
arrhythmias in culture [42].  
  
 
Interstitial cells of Cajal   
Cells termed as the interstitial cells of Cajal (ICC) are found in the human gut. They 
generate spontaneous pacemaker currents propagating electrical signals critical for gut 
peristalsis.  The embryological origin of ICC are from the same embryonic germ layer 
mesoderm as that of heart cells [7, 44]. ICC express Cx43 and form conductive networks via 
these proteins [7]. 
  Cardiac conduction repair by ICC in vitro was recently investigated. Conduction block 
was created by abrasion of synchronously beating monolayer of mouse atrial cells culture in 
MEA dish.  This was co-cultured with ICC isolated from porcine ileum. Synchronous beating 
of cardiomyocytes was observed after addition of ICC. Evidence of in vivo success was also 
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seen after injection of ICC into the right atrium. Tissue sections highlighted that ICC survived 
the injection two weeks later. Demonstration is that ICC could be obtained in high numbers 
from gut and conduct impulses across damaged cardiomyocytes.  Autologous transplantation 
would reduce ethical issues associated with embryonic stem cells and problems with 
immunorejection. Further studies would need to confirm if ICCs could be used for conduction 
repair in vivo [7].  
 
Limiting factors  
Cell therapy offers a novel approach to treating arrhythmias.  Stem cell based biological 
pacemakers have shown success in vivo in animal models, but are yet to meet criteria that 
would allow for successful translation into clinical therapy [17]. Limitations have been 
encountered with regards to their use for cardiac conduction damage.  Whilst success has been 
observed in vitro and in vivo, feasibility and safety still largely unknown and remains 
untested.  Current knowledge is based on studies of short term observation in vitro and there 
are still only a small number of studies that show success for conduction repair in animals [7].  
Although, there is evidence of positive results from in vivo studies examining the ability of 
hESC- CMs to improve cardiac function, numbers of incorporated cells attributed to 
improvements has been low [30, 31]. Difficulties are also faced with regards to obtaining 
quantitative electrophysiological assessment following hESC- CM engraftment in vivo [30, 
31]. Moreover, strong concerns have also been raised regarding the pro-arrhythmic potential 
of cell therapies [39] [40].  
Furthermore, whilst studies using ESCs have shown success there are obvious ethical 
concerns regarding the use of embryonic stem cells [45]. Immunogenic concerns also exist and 
hosts would require immunosuppression [23]. Autologous sources that bypass these problems 
do exist (skeletal myoblasts, pluripotent stem cells) but require genetic engineering [23].  The 
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use of adult cardiac stem cells would counter these concerns however research looking at their 
use for biological pacing is only in its early stages [46, 47]. 
 
Gene mechanisms of ventricular tachycardia and ventricular fibrillation 
As discussed, ventricular tachy-arrhythmias most often occur in the setting of structural heart 
disease. However, genetic disorders including LQTS, Brugada syndrome and 
catecholaminergic-VT, result from ion channel abnormalities and ion dysregulation in the 
context of a structurally normal heart [4]. LQTS is cause by a group of mutations, underpinned 
by a reduction in the repolarising current, thus prolonging the action potential duration [48]. 
The commonest forms of LQTS (types 1,2 and 3) result from loss-of-function mutations to 
potassium channels, and gain-of-function defects to depolarizing sodium current [48]. 
Brugada syndrome is endemic in east and south-east Asia. One third of cases is familial, with 
an autosomal dominant inheritance pattern. Loss of function of the SCN5A (sodium-carrying) 
channel has been identified in 20% of patients [49].  Catecholaminergic polymorphic VT is 
most commonly caused by a mutation to the ryanodine receptor channel, which releases 
calcium from the sarcoplasmic reticulum during the plateau phase of the cardiac action 
potential [50] . 
Use of Gene Therapy to treat VT/VF 
Sarcoplasmic reticulum Ca ATPase (SERCA) 2a is an ATPase pump that regulates cytosolic 
calcium concentration by transferring Ca into the lumen of the sarcoplasmic reticulum. 
Following ischaemia, SERCA activity decreases, increasing cytosolic Ca and triggering 
afterdepolarizations [9]. SERCA2a was overexpressed in the left ventricles of pigs who had 
undergone LAD occlusion and reperfusion. There was a significant reduction in arrhythmias 
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of transfected animals compared with controls. There was no difference, however, in animals 
who had undergone artery occlusion but no reperfusion [51]. 
Deficient SERCA2a is also associated with cardiac failure. When transferred into the failing 
hearts of rats [52] and guinae pigs [53], ventricular arrhythmias were significantly suppressed. 
SERCA2a overexpression in the heart of healthy young guinae pigs resulted in a 4-fold 
reduction in alternans-mediated ventricular arrhythmias [54]. 
Another modulator of cytosolic calcium concentration is calsequestrin, which binds calcium 
within the SR. Intraperitoneal injection of WT-CASQ2 into knockout mice normalised levels 
of calsequestrin and its associated proteins, and significantly suppressed catecholaminergic 
arrhythmias [55]. A follow up study demonstrated the curative effects were seen for one year 
after a single vector injection [56].  
Re-entry accounts for most VT/VF. In infarct epicardial border zones the cardiac sodium 
channel is largely inactivated contributing to slow conduction and re-entry [57]. SkM1 carries 
a fast inward sodium current. When injected directly into the infarct border zone, SkM1 
suppressed post-infarct arrhythmias in dogs and increased Vmax of depolarised myocardium 
[58]. The KCNH2 protein forms the hERG1 channel, which mediates the repolarizing K 
current. Transfection of dominant negative mutant prolonged the refractory period and 
suppressed post-infarct arrhythmias in porcine models [59]. 
 
Gene Mechanisms of bradyarrhythmias 
Bradycardia is generally associated with structural heart disease, but genetic cases have been 
identified affecting children with no underlying pathology [5, 60] . Familial sinus bradycardia 
has been linked with a mutation in the HCN4 ion channel[61]. The mutant channels were 
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activated at more negative voltages than the wild-type channels, decreasing the inward diastolic 
current and slowing the heart rate[61]. Mutations to the voltage-gated sodium channel have 
been linked with SCN5A-related familial sick sinus syndrome[62] 
 
Use of Gene Therapy to treat bradyarrhythmias 
Gene therapy has successfully been used to convert normally quiescent cells into pacing cells, 
and to increase the intrinsic rate of cells with pacing ability. 
HCN (hyperpolarisation-activated cyclic nucleotide gated) channels carry the ‘funny’ current 
and are often referred to as the pacemaker channels. They are activated on hyperpolarization 
and allows passage of sodium and potassium. HCN4 is the main isoform found in the sinoatrial 
node, but low levels of HCN1 and HCN2 have been reported. As mutations to this channel 
have been linked with familial sinus bradycardia, several studies used HCN ‘gain-of-function’ 
to increase the heart rate of subjects. 
Transfection of murine-HCN2 into the left atria of dogs results in spontaneous pacemaker 
activity from the left atria after vagal-stimulated sinus arrest. Importantly, the rhythm was 
generated from the site of injection on electrophysiological studies[63].  When HCN2 was 
injected into the LBB of dogs, there was a ventricular rhythm significantly faster than that seen 
in the controls[64].  
Another group created a construct of HCN1-ΔΔΔ (a channel with a shortened S3-S4 linker 
which favours channel opening). The recombinant adenovirus was injected into the left atria of 
porcine models of sick sinus syndrome. Not only did the transfected animals demonstrate a 
physiologically viable heart rate (average 64 bpm) but it responded appropriately to 
catecholaminergic-stimulation [65].  
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Similar viable pacemaker systems were established in rats [66] and in pigs[67] with AV block. 
The former study, however, showed the HCN expression only lasted for one month after 
injection, calling into question the long term feasibility. If the effect is only transient, it could 
be used for short-term ‘bridging’ option for patients e.g. when being treated for a device 
infection. 
Boink et al combined HCN with adenylyl cyclase [68] and SkM1 [69] genes, to assess if the 
addition enhanced the pacemaker ability compared with HCN transfection alone.  When 
injected into LBBB of canine models with AV block, both combinations produced a 
physiologically higher heart rate than HCN alone. 
Heart rate is under control of adrenergic signalling. Edelberg et al used DNA plasmids to 
transfer the B2-adrenergic receptor into the right atrium of otherwise normal pigs, leading to 
50% increase in heart rate, and effect that lasted 2 days[70]. Adenylyl-cyclase type 6 (ACVI) 
is generated in response to b-adrenergic stimulation, and then binds to HCN channels, where 
is regulates spontaneous rhythm activity. After injection into the left ventricle, all animals 
receiving ACVI demonstrated an escape rhythm from the site of injection of >100bpm when 
isoprenalin was also administered. In contrast, the control animals showed an escape rhythm 
from the right ventricle [71]. 
TBX18 (transcription box factor 18) is a transcription factor that is required for SAN 
development in the fetal heart. Adenoviral transfer of TBX18 has successfully created ectopic 
pacemaker activity at sites of injection in guinae pigs [72] and pigs [73]. In the porcine model, 
heart rates were significantly faster in TBX18 recipients compared with controls. Furthermore, 
cells with SAN-morphology were detected at the sites of injection. 
 
16 
 
Gene Mechanisms of Atrial Fibrillation 
Use of gene therapy to treat AF 
Gene therapy can be used to control the heart rate or the heart rhythm, similar to current medical 
therapy. During AF, normal AV conduction leads to a rapid ventricular rate and a reduction of 
cardiac output. Stimulation of b-adrenaline receptors results in release of Gas protein subunits, 
activating adenylyl cyclase. This shortens the refractory period and increases conduction 
through the AV node. Inhibitory G proteins have been transfected into the AV nodes of pigs, 
resulting in a ventricular rate reduction of ~20% [74]. Rather than completely inhibiting the G 
protein, Lugenbiel attenuated the Gas with a silencing RNA (SiRNA). Again a 20% HR was 
observed in transfected animals compared with controls. Alongside the reduction in heart rate, 
a significant increase in LVEF was observed [75]. 
The other medical option is rhythm control. Class III antiarrhythmic drugs work by blocking 
inward K current, and therefore prolonging the action potential and refractory period. Atrial 
repolarization is conducted by the delayed rectifier potassium current. Amit et al transferred a 
dominant-negative mutant of the underlying ether-a-go-go gene, which codes for the potassium 
channel. By day 10, none of the G628S recipients were in AF, but by day 21 all animals were 
in AF [76]. Soucek et al also achieved significant suppression of AF in pigs who were injected 
with adenoviral carriers [77]. 
AF is also associated with reduced expression of connexin40 and 43, which regulate 
conduction velocity in the heart. Adenoviral transfer of both proteins resulted in significant 
suppression of AF in 2 independent studies [78, 79] 
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Conclusions 
It has become evident that cardiac arrhythmias have a gene and cell-related substrate and those 
factors may well account for the presentation of different kind of arrhythmias. So far, the exact 
mechanisms through which genes and cells contribute to cardiac arrhythmias are not fully 
understood. Despite this, ongoing research using cells and genes has opened new horizons in 
the management of arrhythmias. The available results are promising, but still in the pre-clinical 
setting. Therefore, we look forward to future clinical studies, which will confirm the clinical 
utility of those strategies. 
   
Expert opinion 
Cardiac arrhythmias are characterised by high mortality rates especially in patients with pre-
existing cardiac disorders and the elderly. Conduction defects can lead to both tachycardias 
and bradycardias. There is also evidence that cells and genes are closely related to arrhythmias 
and play a significant role in arrhythmogenesis. Therefore, several studies have aimed to 
treat/manage arrhythmias by using cell- and gene-based or combination strategies.  It appears 
that such therapeutic approaches can improve an impaired conduction. Recent clinical and 
experimental studies have assessed the efficacy of gene and cell therapies confirming potential 
antiarrhythmic effects. Some of the studies have shown encouraging results. However, there is 
still lack of large clinical trials using genes and cells to treat arrhythmias. Moreover, traditional 
therapeutic approaches such as drugs, devices and catheter ablation remain superior and well 
evaluated compared to cell and gene-based strategies. Limiting factors still remain the dosage, 
selection, delivery, toxicity and inflammation predisposed by those therapies. It has also been 
shown that some cells proliferate quickly and as a result, these cells may quickly lose the 
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phenotype of the targeted gene transferred for the therapy. In addition, it is speculated that 
repeated gene therapy could prove to be harmful due to host immune responses, while gene 
vectors used currently could potentially result into different diseases. Therefore, it is evident 
that gene and cell-based therapeutic approaches, although promising, are still challenging and 
pose a risk of proarrhythmia. Future large scale studies in this field are required to evaluate the 
potential role of these approaches and to move from the experimental/preclinical setting to the 
application in the clinical practice. 
Acknowledgements: none 
Figure. Summary of potential effects of cell and gene-based therapies on arrhythmias. 
Abbreviations: KCNE3: Potassium voltage-gated channel, Isk-related family, member 3;  
HERG: human Ether-à-go-go-Related Gene; SERCA: sarco/endoplasmic reticulum Ca2+-
ATPase   
 
 
 
Highlights box:  
1. Cardiac arrhythmias are characterised by high mortality rates especially in patients with 
pre-existing cardiac disorders and the elderly. 
2. Genes and cells are involved in the pathogenesis of arrhythmias. 
3. Gene- and cell-based strategies are promising, but still not well evaluated in the clinical 
setting. 
4. Several limiting factors should be taken into consideration before using cell and gene 
therapeutic approaches in clinical practice.  
5. Traditional therapeutic approaches such as drugs, devices and catheter ablation remain 
superior to cell- and gene-based strategies. 
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